Lisa M. Ferri
Lisa M. Ferri is global co-chair of the firm’s Intellectual Property practice and the Life Sciences group. She serves as lead trial and appellate counsel on behalf of high-profile companies in the pharmaceutical, biotechnology and medical device industries. Lisa is a seasoned and versatile litigator having tried high-stakes cases in federal courts across the country and the International Trade Commission, argued before the Patent Trial and Appeal Board (PTAB), and the Federal Circuit Court of Appeals. She has significant experience guiding companies through patent challenges under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act (BPCIA).
Lisa also advises companies and investors in the life sciences industry in transactions involving intellectual property including mergers and acquisitions, collaborations, joint ventures and other strategic commercial arrangements. She combines a litigator’s perspective with intellectual property expertise to evaluate and identify both risks and opportunities for clients. For instance, Lisa recently provided intellectual property counsel to Bristol-Myers Squibb in its $74 billion acquisition of Celgene.
Clients and peers alike recognize Lisa as a leading intellectual property lawyer. Lisa is a Chambers ranked patent lawyer. Chambers USA 2020 states that she is “regularly called upon to handle complex patent disputes” and describes Lisa as an “excellent lawyer” with a “strong life sciences practice.” Managing Intellectual Property has chosen Lisa as one of the “Top 250 Women in IP” every year since the list’s inception in 2013. Who’s Who Legal: Patents 2016-2020 named Lisa as a leading patent litigation lawyer. IAM Patent 1000 has consistently ranked Lisa as a Silver Band leading practitioner. The Legal Media Group named her a “Life Sciences Star” and an “IP Star,” noting that “Lisa is professional, intelligent, people savvy, tough when need be, and has a great command of the applicable law.” LMG Life Sciences Awards considered Lisa a finalist in 2020 and 2018 for “New York General Patent Litigator of the Year,” in 2019 for “Patent Strategist of the Year,” and in 2014 for “Hatch‐Waxman Litigator of the Year.” In addition, she has been recognized in the area of patent litigation by the Legal 500. LMG Life Sciences Awards shortlisted Lisa’s victory at the Federal Circuit Court of Appeals in Biogen IDEC, Inc. and Genentech v. GlaxoSmithKline, a case involving the monoclonal antibody therapy Arzerra® for “Patent Impact Case of the Year.”
Lisa has been recognized for her leadership in the legal industry and her commitment to diversity and inclusion in the profession. The New York Law Journal honored her as one of its Distinguished Leaders for 2018. The award is presented to twenty attorneys in leadership roles across the country who have achieved extraordinary results over the past year. In 2017, she was named to Crain’s New York Business’ inaugural list of “Leading Women Lawyers” in New York City as a trailblazer who juggles a distinguished career and exceptional civic and philanthropic activities. She has also been named a “Woman Worth Watching” by Profiles in Diversity Journal and a “Woman to Watch” by the American Intellectual Property Law Association. Lisa is active in professional organizations devoted to women’s leadership, including as a member of the Advisory Board of Women in Law Empowerment Forum (WILEF).
Lisa serves as Chair of the firm’s global Women’s Leadership Committee and the New York Office Women’s Forum and as a member of the firm’s Diversity Steering Board.
Lisa is an adjunct professor at Fordham University School of Law where she teaches Patent Litigation.